國際新聞精選周四（2017年4月6日）

2017年4月6日 | Filed under: | Posted by: 編輯 D

Sosei Subsidiary Heptares to Receive US$12 Million Milestone Payment from AstraZeneca

Sosei Group Corporation (“Sosei”; TSE Mothers Index:4565) reported that its subsidiary, Heptares Therapeutics (“Heptares”) has announced that it has achieved an important milestone in its immuno-oncology collaboration with AstraZeneca, which is focused on the development of AZD4635 (HTL-1071) as a potential new treatment for a range of cancers. As a result, Heptares has been notified today that the achievement has triggered a US$12 million payment from AstraZeneca.【閱讀原文】

Parkinson’s approach to cancer needs more work

The concept was intriguing: take an adenosine A2A antagonist, a mechanism mainly associated with Parkinson’s disease, and test it in oncology. However, interim data Corvus presented at the AACR meeting yesterday suggest that at best this approach still needs more work.【閱讀原文】

OncoMed Highlights New Data Presented at the American Association for Cancer Research Annual Meeting 2017

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, highlighted data presented during the American Association for Cancer Research (AACR) Annual Meeting related to its clinical trial of tarextumab (anti-Notch2/3, OMP-59R5) and preclinical studies of rosmantuzumab (anti-RSPO3, OMP-131R10) and GITRL-Fc trimer (OMP-OMP-336B11). 【閱讀原文】

Oncolytics Biotech Inc.'s REOLYSIN More than Doubles Overall Survival in Patients with Mutated p53 Metastatic Breast Cancer

Oncolytics Biotech? Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) today announced data demonstrating a statistically significant (p=0.03) overall survival (OS) benefit for patients with mutated p53 metastatic breast cancer, when treated with REOLYSIN?, an immuno-oncology viral agent, in combination with paclitaxel. Results from IND 213, an open-label, randomized, phase 2 study were presented at the Annual Meeting of the American Association of Cancer Research (AACR), April 1-5, 2017 in Washington, D.C. 【閱讀原文】

Novel IDO1 Inhibitor Shows Promise in Early Phase Study

The IDO1 inhibitor BMS-986205 had "best-in-class" activity as demonstrated by kynurenine reductions and IDO1 inhibition for patients with advanced malignancies in a phase I/IIa study, according to lead investigator Lillian L. Siu, MD, at the 2017 AACR Annual Meeting.1

"BMS-986205 is fulfilling the criteria for being a best in class IDO1 inhibitor, it is potent and selective," said Siu, senior medical oncologist at Princess Margaret Cancer Centre. "The once-daily dosing exceeds the IC90 target concentrations. We see kynurenine reduction that is greater than reported with previous IDO1 inhibitors."【閱讀原文】

Immunomedics says IMMU-132 hits targets in small cell lung cancer

Embattled Immunomedics has some good news to report on its lead antibody-drug conjugate (ADC) program with a preliminary study showing IMMU-132 has activity in small cell lung cancer (SCLC).

The data could add another possible indication for IMMU-132, which according to Immunomedics is on course for an accelerated approval later this year for triple-negative breast cancer but will need to be backed up by further studies.【閱讀原文】

DelMar Pharmaceuticals Provides VAL-083 Updates from the Ongoing American Association for Cancer Research (AACR) Annual Meeting

DelMar Pharmaceuticals (Nasdaq: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that it has presented three abstracts at the American Association for Cancer Research (AACR) Annual Meeting. These abstracts are all focused on pre-clinical research to elucidate the mechanism of action (MOA) of DelMar Pharmaceuticals' lead anti-cancer product candidate, VAL-083 (dianhydrogalactitol), a "first-in-class" small-molecule, DNA-targeting, chemotherapeutic agent. 【閱讀原文】

Long-term melanoma data open another Opdivo weak spot

Bristol-Myers Squibb may have celebrated an overall survival win for Opdivo plus Yervoy in melanoma in two-year follow-up data from Checkmate-067, but an overlooked aspect is the study’s failure to provide convincing evidence that the two-drug combination beats single-agent Opdivo.【閱讀原文】

Allergan To Test Botox For Depression Despite Mixed Results

Allergan says it plans to advance its iconic wrinkle treatment, Botox, to late-stage clinical trials, the last step of study before a medicine is approved, based on data from a 258-patient study it is releasing this afternoon.【閱讀原文】

美中藥源原創文章，轉載注明出處并添加超鏈接，商業用途需經書面授權。
★更多深度解析訪問《美中藥源》~

★ 請關注《美中藥源》微信公眾號 ★